Reading the article closer, I'm fairly certain they did not include microspheres which are classified as permanent brachytherapy. Neither Sirtex or Boston Scientific were listed in the companies and liver cancer was not listed as one of the cancers. I expect that these two companies combined may be close to that total alone. I also feel that Radiogel use may be more comparable to that of microsphere use than that of traditional brachytherapy.....bigger upside potential.
Think it makes sense to put the radioembolization devices in their own catagory cuz the application is via arteries feeding tumors, not placed within tumor like Radiogel or seed brachytherapy. Seems like apples and oranges to compare radioembolization to brachytherapy.
News 
Market Data 
Discover 
